Follow
Benjamin Solomon
Benjamin Solomon
Medical Oncologist, Peter MacCallum Cancer Centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
50592010
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
37162013
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
30942014
Clinical features and outcome of patients with non–small-cell lung cancer who harbor EML4-ALK
AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ...
Journal of clinical oncology 27 (26), 4247, 2009
22212009
Crizotinib in ROS1-rearranged non–small-cell lung cancer
AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ...
New England Journal of Medicine 371 (21), 1963-1971, 2014
18542014
Ceritinib in ALK-rearranged non–small-cell lung cancer
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
N Engl j med 370, 1189-1197, 2014
16972014
Comprehensive genomic profiles of small cell lung cancer
J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ...
Nature 524 (7563), 47-53, 2015
15512015
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ...
The lancet oncology 13 (10), 1011-1019, 2012
14512012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers
R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ...
Science translational medicine 4 (120), 120ra17-120ra17, 2012
13342012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ...
Nature genetics 44 (10), 1104-1110, 2012
12882012
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ...
Journal of Thoracic Oncology 13 (3), 323-358, 2018
11672018
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ...
The lancet oncology 12 (11), 1004-1012, 2011
10852011
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ...
Science translational medicine 2 (62), 62ra93-62ra93, 2010
9492010
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial
D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ...
Journal of clinical oncology 28 (27), 4142, 2010
8152010
Rociletinib in EGFR-mutated non–small-cell lung cancer
LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ...
New England Journal of Medicine 372 (18), 1700-1709, 2015
7612015
Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases
DB Costa, AT Shaw, SHI Ou, BJ Solomon, GJ Riely, MJ Ahn, C Zhou, ...
Journal of Clinical Oncology 33 (17), 1881, 2015
6312015
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
6242019
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ...
The Lancet Oncology 19 (12), 1654-1667, 2018
5582018
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
AT Shaw, E Felip, TM Bauer, B Besse, A Navarro, S Postel-Vinay, ...
The Lancet Oncology 18 (12), 1590-1599, 2017
5412017
Assessing tumor infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology …
S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ...
Advances in anatomic pathology 24 (6), 311, 2017
4812017
The system can't perform the operation now. Try again later.
Articles 1–20